{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:03:10Z","timestamp":1789578190599,"version":"build-2803163510"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Endoscopic sleeve gastroplasty (ESG) is a minimally invasive endoluminal procedure for the management of obesity and has become increasingly popular in patients who are poor surgical candidates or who choose against surgical intervention. This study aims to evaluate secular trends of ESG in a large bariatric procedure-specific clinical database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed patients who underwent ESG from 2020 to 2023 from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP). Annual incidence, patient characteristics and trends in 30-day serious adverse events following ESG were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2371 patients (mean age 45y, 85.8% F, mean BMI 40\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) underwent ESG between 2020 and 2023. The number of ESGs increased by 50.5% across the study period. ESG volume increased significantly over time (IRR 1.11 per year, 95% CI 1.07\u20131.15;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Mean BMI increased 7.9% across the study period, rising from 37.8\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      to 40.8\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) (Fig.\u00a01B). Despite the rise in BMI and other pre-procedural comorbidities, there was no statistically significant difference in the incidence of adverse events across the study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The number of ESGs being performed has significantly increased over the past few years. Despite expanding ESG to a higher-risk patient population, the incidence of serious adverse events following ESG has remained extremely low with no significant increase over the study period. As endoscopic techniques continue to evolve, ESG acts as a model for the future of endoluminal therapies in high-risk patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00464-026-13022-x","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:36:54Z","timestamp":1783453014000},"page":"7575-7579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Secular trends of endoscopic sleeve gastroplasty: analysis of the MBSAQIP database"],"prefix":"10.1007","volume":"40","author":[{"given":"Benjamin M.","family":"Moy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Barajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe M.","family":"Savino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-8045","authenticated-orcid":false,"given":"Allison R.","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"13022_CR1","doi-asserted-by":"publisher","unstructured":"Emmerich S, Fryar C, Stierman B et al (2024) Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023. National Center for Health Statistics (U.S.). https:\/\/doi.org\/10.15620\/cdc\/159281","DOI":"10.15620\/cdc\/159281"},{"issue":"7","key":"13022_CR2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1053\/j.gastro.2017.01.044","volume":"152","author":"S Sullivan","year":"2017","unstructured":"Sullivan S, Edmundowicz SA, Thompson CC (2017) Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 152(7):1791\u20131801. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.044","journal-title":"Gastroenterology"},{"issue":"4","key":"13022_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/AS9.0000000000000317","volume":"4","author":"A Alsuhibani","year":"2012","unstructured":"Alsuhibani A, Thompson JR, Wigle PR et al (2012) Metabolic and bariatric surgery utilization trends in the United States: evidence from 2012 to 2021 national electronic medical records network. Ann Surg Open 4(4):e317. https:\/\/doi.org\/10.1097\/AS9.0000000000000317","journal-title":"Ann Surg Open"},{"issue":"1","key":"13022_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.amjsurg.2021.12.022","volume":"224","author":"JA Murtha","year":"2022","unstructured":"Murtha JA, Alagoz E, Breuer CR et al (2022) Individual-level barriers to bariatric surgery from patient and provider perspectives: a qualitative study. Am J Surg 224(1):429\u2013436. https:\/\/doi.org\/10.1016\/j.amjsurg.2021.12.022","journal-title":"Am J Surg"},{"issue":"6","key":"13022_CR5","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.14309\/ajg.0000000000002665","volume":"119","author":"BM Moy","year":"2024","unstructured":"Moy BM, Volk S, Richards B et al (2024) Use of postoperative opioid therapy following endoscopic sleeve gastroplasty. Am J Gastroenterol 119(6):1186. https:\/\/doi.org\/10.14309\/ajg.0000000000002665","journal-title":"Am J Gastroenterol"},{"key":"13022_CR6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042320-125832","author":"RD Dolan","year":"2022","unstructured":"Dolan RD, Schulman AR (2022) Endoscopic approaches to obesity management. Annu Rev Med. https:\/\/doi.org\/10.1146\/annurev-med-042320-125832","journal-title":"Annu Rev Med"},{"issue":"10350","key":"13022_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0140-6736(22)01280-6","volume":"400","author":"BKA Dayyeh","year":"2022","unstructured":"Dayyeh BKA, Bazerbachi F, Vargas EJ et al (2022) Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet 400(10350):441\u2013451. https:\/\/doi.org\/10.1016\/S0140-6736(22)01280-6","journal-title":"Lancet"},{"issue":"6","key":"13022_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.gie.2018.12.012","volume":"89","author":"A Alqahtani","year":"2019","unstructured":"Alqahtani A, Al-Darwish A, Mahmoud AE, Alqahtani YA et al (2019) Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc 89(6):1132\u20131138. https:\/\/doi.org\/10.1016\/j.gie.2018.12.012","journal-title":"Gastrointest Endosc"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-13022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-026-13022-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-13022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:17:54Z","timestamp":1789575474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-026-13022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["13022"],"URL":"https:\/\/doi.org\/10.1007\/s00464-026-13022-x","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Allison R. Schulman is a consultant for Apollo Endosurgery, Boston Scientific, Olympus, MicroTech, and Fractyl, serves on the advisory board for Apollo Endosurgery and Olympus, and receives research\/grant support from GI Dynamics and Fractyl. Drs. Benjamin M. Moy, Rolando Barajas, and Chloe M. Savino have no conflicts of interest or financial ties to disclose.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}